

Liver function tests and fibrosis scores in a rural population in Africa: estimation of the burden of disease and associated risk factors

Geraldine A O'Hara^{1,3*}, Jolynne Mokaya^{2*}, Jeffrey P Hau^{1,3}, Louise O Downs^{2,4}, Anna L McNaughton²,
Alex Karabarinde³, Gershim Asiki^{3,5}, Janet Seeley^{3,6}, Philippa C Matthews^{2,4#} Robert Newton^{3,7#}

¹Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine,
London, United Kingdom

²Nuffield Department of Medicine, University of Oxford, Medawar Building for Pathogen Research,
South Parks Road, Oxford OX1 3SY, UK;

³Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical
Medicine Uganda Research Unit, Entebbe, Uganda;

⁴Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust,
John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK;

⁵African Population and Health Research Center, Nairobi, Kenya;

⁶Department of Global Health and Development, London School of Hygiene and Tropical Medicine,
Tavistock Place, London, UK;

⁷Department of Health Sciences, University of York, York, United Kingdom;

* These authors contributed equally

These authors contributed equally

CORRESPONDING AUTHOR: Philippa Matthews, Email: p.matthews@doctors.org.uk

KEY WORDS

Hepatitis, liver function tests, epidemiology, prevalence, alcohol, alcoholic liver disease, HBV, HIV,
Uganda, Africa, cirrhosis, fibrosis

WORD COUNT: 3999

ACKNOWLEDGEMENTS: Nil

CONFLICTS OF INTEREST: We have no conflicts of interest to declare

34 ABBREVIATIONS

- 35 • ALT – alanine transferase
- 36 • APRI - AST to Platelet Ratio Index
- 37 • ARR – American reference range
- 38 • AST – aspartate transaminase
- 39 • BR – bilirubin
- 40 • BBV – blood borne virus (HIV, HBV, HCV)
- 41 • FIB-4- fibrosis-4
- 42 • GGT – gamma glutamyl-transferase
- 43 • GPC – general population cohort, Uganda
- 44 • GPR - GGT to platelet ratio
- 45 • HBV – hepatitis B virus
- 46 • HCV – hepatitis C virus
- 47 • HIV – human immunodeficiency virus
- 48 • LFTs – liver function tests
- 49 • LRR – local reference range
- 50 • NAFLD – non-alcoholic fatty liver disease
- 51 • PAR – population attributable risk
- 52 • RPR- red cell distribution width to platelet ratio
- 53 • sSA – sub Saharan Africa
- 54 • ULN – upper limit of normal
- 55 • USS – ultrasound scan
- 56 • WHO – World Health Organisation

57

58 ABSTRACT

59
60 **Introduction:** Liver disease is a major cause of morbidity and mortality in sub-Saharan Africa. However,
61 its prevalence, distribution and aetiology have not been well characterised. We examined liver function
62 tests (LFTs) and calculated liver fibrosis scores in a rural population in Uganda.

63 **Methodology:** A cross-sectional survey of LFTs was undertaken in 2011 in a rural population cohort in
64 South-Western Uganda. We classified abnormal LFTs based on reference ranges set in America and in
65 Africa. We derived fibrosis scores (AST to Platelet Ratio Index, fibrosis-4, GGT to platelet ratio, red cell
66 distribution width to platelet ratio, and S-index) to evaluate the potential prevalence of liver disease. We
67 collected information about alcohol intake, and infection with HIV, HBV and HCV, to determine the
68 contribution made by these factors to liver inflammation or fibrosis.

69 **Results:** Data were available for 8,099 participants (median age 30 years; 56% female). The prevalence
70 of HBV, HCV and HIV infection were 3%, 0.2% and 8%, respectively. The prevalence of abnormal LFTs
71 was higher based on the American reference range compared to the African reference range (e.g. for AST
72 13% vs 3%, respectively). The prevalence of AST/ALT ratio >2 was 11%, suggestive of alcoholic
73 hepatitis. The highest prevalence of fibrosis was suggested by the GPR score, with 24% of the
74 population falling above the threshold for fibrosis. By multivariate analysis, elevated LFTs and fibrosis
75 scores were most consistently associated with older age, male sex, being under-weight, infection with
76 HIV or HBV, and alcohol consumption. Based on population attributable risk, the highest proportion of
77 elevated fibrosis scores was associated with alcohol use (e.g. 64% of elevated S-index scores).

78 **Conclusion:** Further work is required to determine normal reference ranges for LFTs in this setting, to
79 evaluate the specificity and sensitivity of fibrosis scores, and to determine aetiology of liver disease.

30

KEY FINDINGS

What is already known?

- Liver disease is not well characterised in many parts of sSA despite the high prevalence of chronic viral infections (HIV, HBV and HCV), and potential exposure to hepatotoxins including alcohol, aflatoxins and traditional herbal medicine.
- Non-invasive blood tests for markers of fibrosis are relatively simple and offer a safe route to assess for liver fibrosis, however, their diagnostic accuracy is not well established in sSA.
- Appropriate reference ranges for LFTs are crucial for optimising the sensitivity and specificity of the detection of underlying liver disease.

What are the new findings?

- There is a disparity in the prevalence of abnormal LFTs in our study cohort when comparing two reference ranges (American vs. local reference ranges).
- Based on GPR score, there is a high prevalence of liver fibrosis (almost 1 in 4 of this population) and elevated GPR score is associated with older age, male sex, being underweight, infection with HIV or HBV, and alcohol consumption.
- Alcohol consumption accounted for 64% of abnormal S-index scores, 32% of elevated FIB-4 scores, and 19% of GPR abnormalities.

What do the new findings imply?

- Appropriate reference ranges for LFTs are necessary to contribute to an understanding of the burden and aetiology of liver disease.
- Alcohol, HIV and HBV are risk factors for deranged LFTs and liver fibrosis, with alcohol making the most significant and striking contribution.
- Further investigation is needed to determine other factors that contribute to liver disease in this setting.

INTRODUCTION

Liver disease causes an estimated 200,000 deaths each year in sub-Saharan Africa (sSA) as a result of liver cirrhosis and hepatocellular carcinoma (1). More than 80% of Africa's burden of liver disease has been attributed to endemic blood borne virus (BBV) infections, such as HIV, hepatitis B (HBV) and hepatitis C (HCV), alcohol, hepatotoxic medications (including traditional and herbal medicines), non-alcoholic fatty liver disease (NAFLD) and exposure to aflatoxins (1–3). However, the prevalence, distribution and aetiology of liver disease in many parts of Africa have not been well characterised, and the neglect of cirrhosis has recently been highlighted (2). In order to improve screening for liver disease, and to implement appropriate investigations and intervention, we have undertaken a survey of liver function tests (LFTs) together with demographic data for a large rural cohort in South-Western Uganda (4).

LFTs are usually the first approach to evaluation of liver disease (reference ranges and causes of derangement are summarised in Suppl Table 1). In addition, liver synthetic function can be assessed by measuring prothrombin time; platelet production may be decreased in chronic liver disease due to hypersplenism, decreased thrombopoietin levels and bone marrow suppression (5). Abnormal LFTs are often non-specific and can arise transiently in association with many acute illnesses or usage of medications. However, persistent derangement can indicate chronic liver disease, with associated morbidity and mortality (6). The pattern of derangement can sometimes help to establish aetiology – for example AST/ALT ratio >2 is characteristically associated with alcoholic hepatitis (7,8).

Determination of the origin of liver disease and ascertainment of treatment requirements necessitates accurate characterisation of the degree of liver disease. Liver biopsy allows objective grading of fibrosis and can provide information about the likely aetiology of liver disease based on specific changes to cellular architecture. However, biopsy is costly, requires experts to undertake the procedure and analyse samples, and exposes patients to potentially life-threatening risks. Imaging can also be employed to assess fibrosis. Typically, this comprises ultrasound-based techniques, including fibroscan to derive elastography scores. In most low and middle-income settings, evaluation of liver disease currently depends on use of non-invasive (blood) markers, combined with ultrasound and/or fibroscan when available.

Non-invasive fibrosis blood tests are relatively simple and offer a safe route to assess for liver fibrosis, appealing in resource limited settings. Scores of liver fibrosis, such as AST to Platelet Ratio Index (APRI), fibrosis-4 (FIB-4), GGT to platelet ratio (GPR), red cell distribution width to platelet ratio (RPR) and S-

10 index have been derived using liver enzymes (ALT, AST, GGT) in combination with platelet count.
11 However diagnostic accuracy is not well established in sSA and can be influenced by the population
12 being assessed and the nature of underlying liver disease (9–14). GPR has recently been reported as an
13 independent predictor of significant fibrosis in treatment naïve Gambian patients with chronic hepatitis B
14 (CHB) infection (12). However, further studies are needed to determine the specificity and sensitivity of
15 different scores in different settings.

16
17 Appropriate reference ranges for LFTs are crucial for optimising the detection of underlying liver disease
18 (15). Application of reference ranges defined in one setting to different populations may lead to either
19 under- or over-estimation of abnormalities (15–17). As well as being dependent on the population being
20 assessed, the distribution of LFTs in any given setting can also be influenced by the type of instrument,
21 reagents used, and the strength of quality assurance (17). Efforts have been made to establish
22 'population-specific' reference ranges (16,18); one example is through the application of cross-sectional
23 data from seven South-Eastern African countries (16). However, such local reference ranges for Africa
24 have been derived from cross-sectional data collected in adults without addressing the potential
25 prevalence of underlying liver disease. Thus, while American reference ranges potentially over-estimate of
26 the burden of liver disease in an African setting, it is also possible that locally derived reference ranges
27 under-estimate the burden (as they are based on thresholds that have been derived from populations in
28 which liver disease is highly prevalent).

29
30 We here set out to assess LFTs and fibrosis scores derived from a large, well defined population cohort in
31 rural South-Western Uganda (19). We applied reference ranges set in both America and in Africa (16,20),
32 in order to assess the possible burden of liver disease, highlighting the discrepancies that arise as a result
33 of the difference between thresholds. We derived fibrosis scores to further evaluate the potential
34 prevalence of liver disease in this setting and to estimate the contributions of alcohol and BBVs to the
35 burden of disease.

36 **METHODS**

37 **Study design and study population**

38
39 We conducted a cross-sectional study in a rural population in Kyamulibwa, in the Kalungu district of
40 South-Western Uganda as part of the survey of the General Population Cohort (GPC). The GPC is a
41 community-based cohort established in 1989 with funding from the UK Medical Research Council (MRC)
42 in collaboration with the Uganda Virus Research Institute (UVRI) (21). Regular census and medical

73 surveys have been conducted in this population cohort. In 2011, data collection included screening for
74 viral hepatitis and LFTs among 8,145 adults (≥ 16 years), which we used for this analysis.

76 **Data collection**

77 Demographic and health history data were collected using questionnaires and standardised procedures
78 described elsewhere (21,22). Blood samples were drawn at home and transported for testing at the
79 Medical Research Council central laboratories in Entebbe. LFTs (serum AST, ALT, ALP, GGT and BR)
80 were measured using a Cobas Integra 400 plus machine, with Roche reagents. Screening for HIV testing
81 was done using an algorithm recommended by the Uganda Ministry of Health, based on initial screening
82 with a rapid test. If the test result was negative, the participant was considered to be HIV negative. If the
83 test result was positive, the sample was re-tested with the rapid test HIV-1 or -2 Stat-Pak. If both tests
84 resulted in a positive result, the participant was diagnosed as HIV positive. If the tests gave discordant
85 results, the sample was further evaluated with the rapid test Uni-Gold Recombinant HIV-1/2. For those
86 samples assessed by all three tests, two positive test results were interpreted as positive, and two
87 negative results were considered negative. HBV surface antigen (HBsAg) testing was conducted using
88 Cobas HBsAg II (2011-08 V10), and those who tested positive were invited for further serologic testing.
89 HCV was tested using a combination of immunoassays followed by PCR, as previously described (23).
90 Normal serum levels of liver enzymes were classified according to the American reference range (ARR,
91 MGH Clinical Laboratories) and Local Reference Ranges (LRR, (16); Suppl Table 1). We excluded
92 individuals ≤ 19 years from ALP analysis, since elevated ALP can be attributable to bone growth in
93 teenagers.

94
95 Data from the full blood count was used to calculate fibrosis scores (mean corpuscular volume, MCV
96 and platelet count). This was collected starting part-way through the 2011 data collection period; the
97 data are, therefore, population-based, although based on only a subset of the whole cohort ($n=1,877$).

99 **Calculation of fibrosis scores and AST/ALT ratio**

100 Where data were available ($n=1,877$), we calculated APRI, FIB-4, GPR, RPR and S-Index. The formulae
101 for calculating these scores are presented in Suppl Table 2, along with the sensitivity and specificity of
102 each, based on previous studies. We used previously established thresholds to suggest the presence of
103 liver fibrosis, as follows: APRI > 0.7 (24), FIB-4 > 3.25 (25), GPR > 0.32 (12), RPR > 0.825 (26), S-index
104 > 0.3 (27). We calculated AST/ALT ratio; a score > 2 has been associated with alcoholic hepatitis (8).

106 **Statistical Analysis**

17 We analysed data using standard statistical software, Stata/IC 13 (Stata Corporation, College Station,
18 USA) and GraphPad Prism v7.0. We summarised participant baseline characteristics using proportions
19 (%) and these were stratified by sex. We reported prevalence and distribution of LFTs, laboratory markers
20 of fibrosis and elastography scores using descriptive statistics. We reported p-values from chi-square
21 tests, comparing the proportions of each potential risk factor between male and female participants.

22
23 We used logistic regression in our univariate and multivariate analyses, using the threshold for
24 significance set at 0.05, to estimate the odd ratios (OR), along with its 95% confidence intervals (95% CI),
25 to identify potential factors associated with abnormal LFTs and liver fibrosis scores, using a forward
26 stepwise approach to develop our multivariate models. We added risk factors that were identified in the
27 age and sex adjusted univariate analysis to the multivariate model. The final multivariate models for each
28 LFT and liver fibrosis score were obtained by excluding variables in the final model until all remaining
29 variables were associated with abnormal LFTs and liver fibrosis scores at the $p < 0.05$ threshold. Once the
30 final multivariate model had been established, variables that were eliminated through this forward
31 stepwise approach were added back to the model and were reported if associated at the $p < 0.05$
32 threshold, to reduce the effects of residual confounding. Due to the low number of individuals with active
33 HCV infection at the time of the study, we did not include this sub-group in univariate or multivariate
34 analysis. These HCV RNA positive individuals have been described in more detail elsewhere (28). We
35 present results of multivariate analysis in the form of Forrest plots generated using Microsoft Excel. A
36 tabular form of the multivariate analysis containing the adjusted odds ratios (Adj. OR), and 95% CIs are
37 included in the supplementary section of the manuscript.

38 **Ethics**

39 Ethics approval was provided by the Science and Ethics Committee of the Uganda Virus Research
40 Institute (GC/127/12/11/06), the Ugandan National Council for Science and Technology (HS870), and the
41 East of England-Cambridge South (formerly Cambridgeshire 4) NHS Research Ethics Committee UK
42 (11/H0305/5). All participants provided written informed consent.

43 **RESULTS**

44 **Characteristics of study population**

45 We analysed complete data for 8,099 participants (Suppl Table 3). Compared to females, there were
46 more males who were HBV positive, (prevalence 3% vs 2%, respectively; $p < 0.001$) and had consumed
47 alcohol in the past 30 days, (40% vs 33%, respectively; $p < 0.001$). More females were HIV positive (9%

vs 6%, respectively; $p < 0.001$). Males were more likely to be underweight (31% vs 16%), and females to be overweight (18% vs 5%); $p < 0.001$ in both cases.

Proportion of population defined as having abnormal LFTs varies according to the reference range that is applied

The proportion of the population falling above the upper limit of normal (ULN) for each parameter is shown in Table 1, with ALT, AST and GGT distributions in Fig 1A-C (full data for all LFTs are shown in Suppl Fig 1). These results highlight the different burden of disease that can be estimated according to the reference range that is applied, with a higher proportion of the population falling above the ULN when the ARR was applied compared to the LRR (Fig 1A, B). Most striking, for AST, 13% of the population had a value that was deemed to be elevated based on ARR, compared to only 3% based on the LRR (Fig 1B). Using the ARR, ALT and BR were significantly more likely to be above the ULN in males than in females, and ALP was more likely to be higher in females ($p < 0.001$ in each case, Table 1). These sex differences were not apparent when the LRR was applied. OR for deranged LFTs and fibrosis scores according to age and sex is shown in Suppl. fig 2.

The highest prevalence of liver fibrosis is predicted using the GPR score

We calculated APRI, FIB-4, GPR, RPR and S-index scores (Table 1). The estimated prevalence of fibrosis was highest when based on GPR score (23.5%; Fig 1D), compared to FIB-4 (5.3%), APRI (3.2%), S-index (3.9%) and RPR (0.1%). We excluded RPR scores from further statistical analysis because so few individuals were classified as having an elevated score (we therefore did not have statistical power to detect any factors associated with abnormal score). Because the APRI is derived using the ULN of AST, the proportion of the population classified as having a score consistent with liver fibrosis changes according to whether the ARR or LRR is used (Table 1). Based on previous validation among African individuals, there is evidence to suggest that GPR is the most accurate score for staging liver fibrosis (12); applying this approach, there is a prevalence of almost 1 in 4 adults with liver fibrosis in this population.

Evidence for the contribution of alcohol to liver disease

The prevalence of AST/ALT ratio > 2 , suggestive of alcoholic hepatitis, was 11% (888/8,099) (Fig 1E). There was a significant relationship between self-reported alcohol consumption and elevated AST/ALT ratio ($p < 0.001$; Suppl Fig 3). However, 57% of participants with AST/ALT ratio > 2 reported never having consumed alcohol (Fig 1E), possibly reflecting either under-reporting of alcohol use and/or other factors that underpin this pattern of LFTs. Self-reported alcohol consumption was associated with raised LFTs,

74 as follows: ALT (Adj. OR 1.33, 95% CI 1.09,1.63) AST (Adj. OR 1.53, 95% CI 1.30, 1.78) GGT (Adj.
75 OR 2.00 95% CI 1.69, 2.36), and with abnormal fibrosis scores, particularly GPR (Adj. OR 1.96, 95%
76 CI 1.52, 2.54). All ORs, adjusted ORs, their respective 95% confidence intervals and p-values are
77 shown in Table 2, and selected variables in Fig 2.

78
79 A raised GGT level in combination with AST/ALT ratio >2 can be used to increase the sensitivity of
80 detection of alcoholic hepatitis (8). GGT levels were significantly higher among males with AST/ALT ratio
81 ≥ 2 ($p < 0.001$), but there was no relationship between GGT and AST/ALT ratio in females ($p = 0.7$); Suppl
82 Fig 4. This potentially indicates that alcohol is of more influence as a cause of an elevated AST/ALT ratio
83 in men than in women. There was no significant association between AST/ALT ratio ≥ 2 and the presence
84 of an elevated GPR score, predicting fibrosis ($p = 0.2$; data not shown). We calculated population
85 attributable risk (PAR) as a way to assess the relative contribution of different risk factors to the overall
86 burden of liver disease; Table 3. Overall, the most striking contribution arose from reported alcohol
87 consumption, which accounted for 64% of abnormal S-index scores, 32% of elevated FIB-4 scores, and
88 19% of GPR abnormalities.

90 **Abnormal LFTs and/or elevated fibrosis scores are associated with sex, age, and body mass** 91 **index**

92 Females were less likely to have high fibrosis scores based on FIB-4 compared to males (Adj. OR:
93 0.6), APRI (Adj. OR: 0.42), and S-Index (Adj. OR: 0.37) compared to males. FIB-4 score increased
94 markedly with age: adults aged 40 – 49 (Adj. OR: 7.04), 50 – 59 (Adj. OR: 11.29), and adults >60
95 years (Adj. OR: 25.15) were more likely to have a higher FIB-4 than individuals < 39 years. Elevated
96 BMI was associated only with a rise in GGT (Adj. OR: 1.47). However, being underweight was
97 associated with a more pronounced pattern of liver derangement, including elevations in ALT (Adj. OR:
98 1.40), AST (Adj. OR: 1.44), GGT (Adj. OR: 1.37), abnormal fibrosis scores (APRI Adj. OR: 1.72,) and
99 with raised AST/ALT ratio (Adj. OR: 1.61). 95% CI in each case are shown in Table 2.

101 **Relationship between HBV infection and liver disease**

102 HIV infection was associated with abnormal liver function tests, with significant OR for increased ALT,
103 AST, ALP and GGT, as well as with raised GPR and S-index (on univariate and multivariate analysis;
104 Table 2). HBV infection was significantly associated with a rise in hepatic transaminases (OR for raised
105 ALT and AST 2.6 and 2.4 respectively, on multivariate analysis), and with liver fibrosis as measured by
106 APRI and GPR (OR 3.6 and 4.2 respectively, on multivariate analysis). We investigated the prevalence
107 of HBV infection among individuals with raised fibrosis scores. There was an association between the

presence of HIV or HBV and raised GPR ($p=0.005$) and S-Index ($p<0.001$). Therefore, GPR and S-Index may be the most sensitive markers of inflammation and/or fibrosis in the context of HBV or HIV infection. HIV and HBV were associated with a lesser proportion of liver disease than alcohol based on calculation of PAR (Table 3), but still contributed to elevations in both LFTs and fibrosis scores. The OR for deranged LFTs/fibrosis scores in the context of HIV or HBV infection is shown in Fig 2.

Liver disease of unknown aetiology

Among individuals with $GPR>0.32$, 33.8% had either BBV infection or had $AST/ALT>2$ (suggesting potential alcoholic hepatitis) (Fig 1D; Suppl Fig 5). However, this illustrates that 66% have raised fibrosis scores in the absence of a history of alcohol use, or HIV or HBV infection, suggesting that other factors unaccounted for in this study are likely to be contributing to the overall burden of liver disease. True prevalence of liver disease cannot be ascertained until reference ranges have been more carefully defined, correlating LFTs and fibrosis scores with the confirmed presence of underlying liver disease based on imaging or biopsy.

DISCUSSION

Liver disease is not well characterised in many parts of sSA despite the high prevalence of HIV and HBV, and potential exposure to hepatotoxins (1,3). In this study, we used cross-sectional data from a large population cohort to estimate the burden of liver disease and to assess the possible impact of BBV infection and alcohol consumption. The prevalence of abnormal LFTs depends on the reference range that is applied. The ARR suggests a higher prevalence of liver disease, therefore including more false-positives. The LRR was established based on individuals recruited from several countries across Africa (Rwanda, Uganda, Kenya, Zambia) (16). While the values were derived from purportedly healthy adults, it is impossible to rule out a high background prevalence of underlying liver disease; in defining higher values for the ULN of all tests, the LRR is more susceptible to false-negatives if used to screen for liver disease.

LFTs are a blunt tool for assessment of liver health, with many potential confounding factors. This current study only accounts for a limited range of aetiological agents, and we did not include other potentially relevant factors such as Schistosomiasis infection, exposure to aflatoxin and use of traditional medications. Furthermore, LFTs were measured at only one point in time, potentially overcalling liver disease as a result of transient abnormalities.

41 Composite fibrosis scores have been developed with the aim of improving sensitivity of detection of liver
42 disease (29), but these scores also depend on platelet count which can be influenced by diverse factors.
43 For example, in some African populations, thrombocytopenia is common due to infections such as
44 malaria, schistosomiasis, HIV or endemic parasites, as well as being influenced by inflammatory
45 conditions and certain drugs (9,10). We only had platelet counts for a sub-set of our study population,
46 limiting the number for whom we could determine APRI, FIB-4, GPR, S-Index and RPR scores. Data
47 surrounding the use of these scores in sSA is variable, but since in many low-income settings alternative
48 diagnostic equipment is unavailable, non-invasive approaches are vital to estimate liver damage and to
49 stratify clinical management decisions.

50
51 APRI and FIB-4 are currently recommended by the World Health Organisation (WHO) for assessment of
52 hepatic fibrosis in patients with chronic HBV or HCV infection (30,31). However, there is evidence
53 showing that APRI is more accurate in assessing liver fibrosis among individuals with chronic HCV
54 compared to HBV infection (11). GPR and S-Index have been validated in small studies in sSA, and have
55 been associated with improved classification of liver fibrosis in chronic HBV infection when compared to
56 APRI and FIB-4 (12–14). It is apparent that either larger studies, or indeed a meta-analysis, are required
57 to further assess the accuracy of these tests in different populations. GPR and S-index may be
58 worthwhile options to include in routine clinical practice to assess for liver fibrosis in African populations,
59 given the high burden of HBV in this continent (32,33). RPR has been used to detect fibrosis among
60 individuals with chronic HBV in China (26), however this score was excluded from our analysis due to a
61 very small number of individuals falling above the suggested threshold for fibrosis.

62
63 The prevalence of AST/ALT ratio >2 in this population is 11%, suggesting potential alcoholic hepatitis
64 (34), concordant with a previous study in Uganda in which 10% of the population was estimated to have
65 alcoholic hepatitis (35), and with data from Uganda's non-communicable diseases risk factor survey which
66 estimated that almost 10% of Ugandan adults have alcohol use disorders (36). Data from emergency
67 attendances at Mulago Hospital in Kampala recorded 47% who reported alcohol use, while 21% and
68 10% met the study definitions of alcoholic misuse and alcoholic liver disease, respectively (35). Our
69 data are based on self-reported alcohol consumption so may underestimate the true extent of alcohol use.
70 We were unable to quantify alcohol intake or the nature of the alcohol consumed: this is challenging as
71 alcohol is often home-brewed or home-distilled from locally grown grains or fruits, and the alcohol content
72 may vary widely; e.g. the alcohol content of locally produced maize-based brews and liquor in Kenya
73 ranged from 2%-7% and 18%-53%, respectively (36). The global challenge of morbidity and mortality
74 associated with alcohol use is highlighted by recent studies from the Global Burden of Disease

75 consortium, in which alcohol ranks as the seventh highest cause of DALYs and deaths and worldwide
76 (2), and together with HBV infection is a leading aetiological agent of liver cancer (37).

77
78 Abnormal LFTs are common in HIV infection for diverse reasons including direct cytopathic effects of HIV
79 on the hepatocytes, co-infection with other BBVs, opportunistic infection, malignancy, ART or other drugs,
80 or secondary to other factors such as alcoholism (38–41). Although a proportion of our study population
81 with fibrosis were infected with BBV (21.6%) and/or had a history of alcohol consumption (12.2%), there
82 was a residual proportion with scores suggestive of fibrosis and AST/ALT ratio >2 who cannot be
83 accounted for through either alcohol or BBV infection. This implies that other factors contribute towards
84 liver dysfunction in this population; a recently published article reported approximately 30% of liver
85 cirrhosis in Africa are not attributed to HBV, HCV, or alcohol misuse and could be as a result of other
86 understudied factors such as NAFLD and use of traditional medicine (35). Aflatoxin exposure is
87 associated with liver cirrhosis and is among the major causes of hepatocellular carcinoma globally, with
88 most cases reported from sSA. Within a previous study of the GPC, >90% of individuals had evidence of
89 exposure (42–44).

90
91 In our population women were significantly more likely to be overweight women than men. This may be
92 associated with a higher incidence of NAFLD in women. However, typically only mild rises in ALT are
93 seen, and 80% of those with NAFLD have normal LFTs (45–47) so may not be identified within our current
94 dataset. Diagnosis of NAFLD therefore depends on ultrasound scan (USS); previous studies have
95 consistently shown 70-80% of obese patients have NAFLD on imaging (46,48,49). These imaging
96 modalities were not available in our population, so we are unable to comment specifically on the possible
97 prevalence of NAFLD. Interestingly, in this setting low body weight was more associated with deranged
98 LFTs and with biochemical evidence of liver fibrosis, suggesting a range of pathology that may contribute
99 to liver disease, including organ-specific effects of under-nutrition or stunting (37), as well as the effect of
100 general systemic illness. Further studies are required to investigate the specific relationship between BMI
101 and liver fibrosis in African populations.

102
103 In African populations, HCV infection has frequently been often over-reported due to a reliance on HCV-
104 antibody (HCV-Ab) testing, which detects not only current infection but also previous exposure, and is
105 known to be susceptible to false positive results (28). In this cohort, 298/8145 (3.7%) individuals tested
106 HCV-Ab positive, but among these only 13 were HCV RNA positive (overall prevalence 13/8145 =
107 0.2%).

108

l9 Appropriate reference ranges for LFTs are necessary to contribute to an understanding of the burden and
l10 aetiology of liver disease. Further work is required to determine appropriate thresholds for the ULN of
l11 different parameters in different settings in sSA, and to determine which fibrosis score is most specific,
l12 through application of a more widespread approach to elastography and/or other imaging. At present, we
l13 have identified alcohol, HIV and HBV as risk factors for deranged LFTs and liver fibrosis, with a striking
l14 contribution made by alcohol, but further investigation is needed to determine other risk factors that
l15 contribute to liver disease in this setting.

l16

17 **DECLARATIONS:**

18
19 **CONSENT TO PUBLISH**

20 All authors approve the publication of this manuscript

21
22 **DATA AVAILABILITY STATEMENT FORMAT GUIDELINES**

23 All data generated or analysed during this study are included in this published article (and its
24 Supplementary Information files).

25
26 **CONFLICT OF INTEREST**

27 We have no conflicts of interest to declare.

28
29 **FINANCIAL SUPPORT**

30 The General Population Cohort is jointly funded by the UK Medical Research Council (MRC) and the UK
31 Department for International Development (DFID) under the MRC/DFID Concordat agreement. The work
32 on liver function also received additional funding from the MRC, (grant numbers G0801566 and
33 G0901213-92157). JM is funded by a Leverhulme Mandela Rhodes Scholarship. PCM is funded by the
34 Wellcome Trust, grant number 110110. LOD is funded by NIHR.

35
36 **AUTHORS' CONTRIBUTIONS:**

- 37
- 38 • Conceived the study : GAO, PCM, RN
 - 39 • Data collection : AL, GA, RN
 - 40 • Analysed the data : JM, JPH, PCM
 - 41 • Wrote the manuscript : GAO, JM, JPH, LOD, PCM, RN
 - 42 • Revised the manuscript : All authors

43 All authors have read and approved the manuscript

44 **ACKNOWLEDGEMENTS**

45 Nil

46

17 REFERENCES

- 19 1. Spearman CW, Sonderup MW. Health disparities in liver disease in sub-Saharan Africa. Vol. 35,
50 Liver International. 2015. p. 2063–71.
- 51 2. Vento S, Dzudzor B, Cainelli F, Tachi K. Liver cirrhosis in sub-Saharan Africa: neglected, yet
52 important. *Lancet Glob Heal*. 2018;6(10):e1060–1.
- 53 3. Price JC, Thio CL. Liver Disease in the HIV-Infected Individual. *Clin Gastroenterol Hepatol*.
54 2011;8(12):1002–12.
- 55 4. Hotez PJ, Kamath A. Neglected tropical diseases in sub-saharan Africa: review of their
56 prevalence, distribution, and disease burden. *PLoS Negl Trop Dis*. 2009 A;3(8):e412.
- 57 5. Mitchell O, Feldman DM, Diakow M, Sigal SH. The pathophysiology of thrombocytopenia in
58 chronic liver disease. *Hepat Med*. 2016;8:39–50.
- 59 6. Radcke S, Dillon JF, Murray AL. A systematic review of the prevalence of mildly abnormal liver
60 function tests and associated health outcomes. *Eur J Gastroenterol Hepatol*. 2015;27(1):1–7.
- 61 7. Botros M, Sikaris KA. The de ritis ratio: the test of time. *Clin Biochem Rev*. 2013 34(3):117–30.
- 62 8. Limdi JK. Evaluation of abnormal liver function tests. *Postgr Med J*. 2003;79:307–12.
- 63 9. Huang R, Jia B, Wang G, Wu C. Non-invasive fibrosis markers for chronic hepatitis B in sub-
64 Saharan Africa. *Liver Int*. 2017;37(11):1738–1738. A
- 65 10. Vaughan JL, Fourie J, Naidoo S, Subramony N, Wiggill T, Alli N. Prevalence and causes of
66 thrombocytopenia in an academic state-sector laboratory in Soweto, Johannesburg, South Africa.
67 *S Afr Med J*. 2015;105(3):215–9.
- 68 11. Yilmaz Y, Yonal O, Kurt R, Bayrak M, Aktas B, Ozdogan O. Noninvasive assessment of liver
69 fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with
70 chronic liver disease: APRI in chronic liver disease. *Hepat Mon*. 2011;11(2):103–6.
- 71 12. Lemoine M, Shimakawa Y, Nayagam S, Khalil M, Suso P, Lloyd J, et al. The gamma-glutamyl
72 transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with
73 chronic HBV infection in West Africa. *Gut*. 2016;65(8):1369–76.
- 74 13. Tag-Adeen M, Omar MZ, Abd-Elsalam FM, Hasaneen A, Mohamed MA, Elfeky HM, et al.
75 Assessment of liver fibrosis in Egyptian chronic hepatitis B patients. *Medicine (Baltimore)*.
76 2018;97(6):e9781.
- 77 14. Desalegn H, Aberra H, Berhe N, Gundersen SG, Johannessen A. Are non-invasive fibrosis
78 markers for chronic hepatitis B reliable in sub-Saharan Africa? *Liver Int*. 2017 37(10):1461–7.
- 79 15. Mu R, Chen W, Pan B, Wang L, Hao X, Huang X, et al. First definition of reference intervals of liver
80 function tests in China: a large-population-based multi-center study about healthy adults. *PLoS*

- 31 One. 2013;8(9):e72916.
- 32 16. Karita E, Ketter N, Price MA, Kayitenkore K, Kaleebu P, Nanvubya A, et al. CLSI-derived
33 hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa.
34 PLoS One. 2009;4(2).
- 35 17. Melkie M, Yigeremu M, Nigussie P, Asrat S, Gebreegziabher T, Teka T, et al. Robust reference
36 intervals for liver function test (LFT) analytes in newborns and infants. BMC Res Notes. 2012.
37 5:493.
- 38 18. Rustad P, Felding P, Franzson L, Kairisto V, Lahti A, Mårtensson A, et al. The Nordic Reference
39 Interval Project 2000: recommended reference intervals for 25 common biochemical properties.
40 Scand J Clin Lab Invest. 2004;64(4):271–84.
- 41 19. Neuschwander-Tetri BA, Unalp A, Creer MH, Nonalcoholic Steatohepatitis Clinical Research
42 Network. Influence of local reference populations on upper limits of normal for serum alanine
43 aminotransferase levels. Arch Intern Med. 2008;168(6):663–6.
- 44 20. Stevens W, Kamali A, Karita E, Anzala O, Sanders EJ, Jaoko W, et al. Baseline Morbidity in 2,990
45 Adult African Volunteers Recruited to Characterize Laboratory Reference Intervals for Future HIV
46 Vaccine Clinical Trials. PLoS One. 2008;3(4):e2043.
- 47 21. Asiki G, Murphy GA V, Baisley K, Nsubuga RN, Karabarinde A, Newton R, et al. Prevalence of
48 dyslipidaemia and associated risk factors in a rural population in South-Western Uganda: a
49 community based survey. PLoS One. 2015;10(5):e0126166.
- 50 22. Murphy A, Av G, Rebecca N, Elizabeth H. Sociodemographic distribution of non-communicable
51 disease risk factors in rural Uganda: a cross-sectional study. Int J Epidemiol 2013.
52 2014;42(6):1740–1753.
- 53 23. Stockdale AJ, Phillips RO, Geretti AM, HEPIK Study Group. The gamma-glutamyl transpeptidase
54 to platelet ratio (GPR) shows poor correlation with transient elastography measurements of liver
55 fibrosis in HIV-positive patients with chronic hepatitis B in West Africa. Response to: “The gamma-
56 glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in
57 patients with chronic HBV infection in West Africa” by Lemoine et al. Gut. 2016;65(5):882–4.
- 58 24. Lin Z-H, Xin Y-N, Dong Q-J, Wang Q, Jiang X-J, Zhan S-H, et al. Performance of the aspartate
59 aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: An updated
60 meta-analysis. Hepatology. 2011;53(3):726–36.
- 61 25. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple
62 noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology.
63 2006;43(6):1317–25.
- 64 26. Chen B, Ye B, Zhang J, Ying L, Chen Y. RDW to platelet ratio: a novel noninvasive index for

- 15 predicting hepatic fibrosis and cirrhosis in chronic hepatitis B. *PLoS One*. 2013;8(7):e68780.
- 16 27. Tag-Adeen M, Omar MZ, Abd-Elsalam FM, Hasaneen A, Mohamed MA, Elfeky HM, et al.
- 17 Assessment of liver fibrosis in Egyptian chronic hepatitis B patients: A comparative study including
- 18 5 noninvasive indexes. *Medicine (Baltimore)*. 2018 97(6):e9781.
- 19 28. Adland E, Jesuthasan G, Downs L, Wharton V, Wilde G, McNaughton AL, et al. Hepatitis virus
- 20 (HCV) diagnosis and access to treatment in a UK cohort. *BMC Infect Dis*. 2018;18(1):461.
- 21 29. Yap CY, Choon Aw T. Liver Function Tests (LFTs). Vol. 19, *Proceedings of Singapore Healthcare*
- 22 □. 2010
- 23 30. World health Organisation: Guidelines for the care and treatment of persons diagnosed with
- 24 chronic hepatitis C virus infection. 2018.
- 25 <http://apps.who.int/iris/bitstream/handle/10665/273174/9789241550345-eng.pdf?ua=1>
- 26 31. World health Organisation: Guidelines for the prevention, care and treatment of persons with
- 27 chronic hepatitis B infection. 2015.
- 28 http://apps.who.int/iris/bitstream/handle/10665/154590/9789241549059_eng.pdf?sequence=1
- 29 32. O'Hara GA, McNaughton AL, Maponga T, Jooste P, Ocama P, Chilengi R, et al. Hepatitis B virus
- 30 infection as a neglected tropical disease. *PLoS Negl Trop Dis*. 2017;11(10):e0005842.
- 31 33. Lemoine M, Shimakawa Y, Njie R, Taal M, Ndow G, Chemin I, et al. Acceptability and feasibility of
- 32 a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of
- 33 Liver Fibrosis and Cancer in Africa (PROLIFICA) study. *Lancet Glob Heal*. 2016;4(8):e559-67.
- 34 34. Hall P, Cash J. What is the real function of the liver “function” tests? *Ulster Med J*. 2012;81(1):30–
- 35 6.
- 36 35. Opio CK, Seremba E, Ocama P, Lalitha R, Kagimu M, Lee WM. Diagnosis of alcohol misuse and
- 37 alcoholic liver disease among patients in the medical emergency admission service of a large
- 38 urban hospital in Sub-Saharan Africa; a cross sectional study. *Pan Afr Med J*. 2013;15:23.
- 39 36. Kabwama SN, Ndyabangi S, Mutungi G, Wesonga R, Bahendeka SK, Guwatudde D. Alcohol
- 40 use among adults in Uganda: findings from the countrywide non-communicable diseases risk
- 41 factor cross-sectional survey. *Glob Health Action*. 2016;9(1):31302.
- 42 37. Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, et al. The Burden of Primary
- 43 Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National
- 44 Level. *JAMA Oncol*. 2017;3(12):1683.
- 45 38. Sterling RK, Chiu S, Snider K, Nixon D. The Prevalence and Risk Factors for Abnormal Liver
- 46 Enzymes in HIV-Positive Patients without Hepatitis B or C Coinfections. *Dig Dis Sci*.
- 47 2008;53(5):1375–82.
- 48 39. Osakunor DNM, Obirikorang C, Fianu V, Asare I, Dakorah M. Hepatic Enzyme Alterations in HIV

- 19 Patients on Antiretroviral Therapy: A Case-Control Study in a Hospital Setting in Ghana. *PLoS*
20 *One*. 2015;10(8):e0134449.
- 21 40. Crane M, Iser D, Lewin SR. Human immunodeficiency virus infection and the liver. *World J*
22 *Hepatol*. 2012;4(3):91.
- 23 41. Mata-Marín JA, Gaytán-Martínez J, Grados-Chavarría BH, Fuentes-Allen JL, Arroyo-Anduiza CI,
24 Alfaro-Mejía A. Correlation between HIV viral load and aminotransferases as liver damage
25 markers in HIV infected naive patients: A concordance cross-sectional study. *Virology*. 2009;6:4–7.
- 26 42. Kuniholm MH, Lesi OA, Mendy M, Akano AO, Sam O, Hall AJ, et al. Aflatoxin exposure and viral
27 hepatitis in the etiology of liver cirrhosis in the Gambia, West Africa. *Environ Health Perspect*.
28 2008;116(11):1553–7.
- 29 43. Kang M-S, Nkurunziza P, Muwanika R, Qian G, Tang L, Song X, et al. Longitudinal evaluation of
30 aflatoxin exposure in two cohorts in south-western Uganda. *Food Addit Contam Part A*.
31 2015;32(8):1322–30.
- 32 44. Liu Y, Wu F. Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment.
33 *Environ Health Perspect*. 2010;118(6):818–24.
- 34 45. Almobarak AO, Barakat S, Khalifa MH, Elhoweris MH, Elhassan TM, Ahmed MH. Non alcoholic
35 fatty liver disease (NAFLD) in a Sudanese population: What is the prevalence and risk factors?
36 *Arab J Gastroenterol*. 2014;15(1):12–5.
- 37 46. Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to
38 diagnosis and staging. *Frontline Gastroenterol*. 2014 5(3):211–8.
- 39 47. Onyekwere CA, Ogbera AO, Balogun BO. Non-alcoholic fatty liver disease and the metabolic
40 syndrome in an urban hospital serving an African community. *Ann Hepatol*.;10(2):119–24.
- 41 48. Argo CK, Caldwell SH. Epidemiology and Natural History of Non-Alcoholic Steatohepatitis. *Clin*
42 *Liver Dis*. 2009;13(4):511–31.
- 43 49. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of
44 Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged
45 Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study. *Gastroenterology*.
46 2011;140(1):124–31.
- 47

78 FIGURE LEGENDS

79
30 **Fig 1: Liver function tests and hepatic fibrosis scores among adults in the Uganda General**
31 **Population Cohort.** Distribution of (A) ALT, (B) AST and (C) GGT. Dashed vertical lines indicate upper
32 limit of normal (ULN) based on American reference range, ARR (blue) and local reference range, LRR
33 (red), as shown in Suppl Table 2. Note no LRR for GGT. (D) Proportion of the population with an
34 elevated GPR score, and among those with elevated GPR the proportion with a defined risk factor for
35 fibrosis. (E) Proportion of the population with an elevated AST/ALT ratio, and among those with an
36 elevated ratio the proportion with a self-reported history of alcohol intake.

37
38 **Fig 2: Forrest plots to show odds ratio (OR) for host risk factors and elevated LFTs or fibrosis**
39 **scores in the Uganda General Population Cohort.** Data are presented for the final multivariate model
40 for ALT, AST, APRI, GPR, and AST/ALT and we show variables that were independently associated with
41 the outcome (statistically significant at the $P < 0.05$ level after adjusting for other variables).

42 SUPPLEMENTARY DATA

43 All supporting data are accessible on-line via the following link:

44 <https://figshare.com/s/0b08de8a740991a7aa22> (this will be converted to a permanent DOI on acceptance
45 of the paper).

46
47
48 **Metadata table:** raw data for 8145 adults in the Uganda General Population cohort (available as .xls
49 and .csv files)

50
51 **Supporting data file** (pdf file) contains the following tables and figures:

52
53 **Suppl Table 1: Origin, reference ranges and clinical significance of liver functions tests (LFTs)**

54
55 **Suppl Table 2: Scores to estimate liver fibrosis, calculated from liver function tests**

56
57 **Suppl Table 3: Description of characteristics of study participants with liver function**
58 **test (LFT) results from the Ugandan General Population Cohort (N=8,099)**

59
60 **Suppl Fig 1: Distribution of liver function tests in Uganda General Population Cohort.** Dashed
61 vertical lines indicate upper limit of normal (ULN) based on American reference range, ARR (orange line

is the ULN for female; blue line is the ULN for males) and local reference range, LRR (black), as shown in Suppl Table 1. Note no LRR for GGT. ULN for bilirubin using ARR is the same for both male and female, indicated by red dashed line. Data are shown for study participants aged ≥ 16 years, apart from ALP which is shown for participants aged ≥ 20 to exclude teenagers who may have elevated ALP as a normal physiological consequence of bone growth.

Suppl Fig 2: Odds ratio for deranged ALT, AST, APRI, GPR and AST/ALT among participants grouped by sex and age.

Suppl Fig 3: Proportion of Uganda General Population cohort reporting alcohol consumption among individuals with and without AST/ALT ratio >2

Suppl Fig 4: Proportion of Uganda General Population Cohort with elevated GGT, according to AST/ALT ratio. (A) males, with upper limit of normal GGT=61 (B) females, with upper limit of normal GGT=36. P-values by Fisher's Exact Test.

Suppl Fig 5: Proportion of Uganda General Population Cohort with blood borne virus (BBV) infection, according to GPR score. P-value by Fisher's Exact Test, showing significant enrichment of BBV infection among individuals with elevated GPR score >0.32 .

TABLES

Table 1: Study participants from the Uganda General Population Cohort with abnormal LFT results and fibrosis scores based on upper limit of normal according to American reference range (ARR) and local reference ranges (LRR).

<i>Enzyme Type</i>	<i>Total n / N (%)</i>	<i>Male n / N (%)</i>	<i>Female n / N (%)</i>	<i>p value¹</i>
ALT²				
Abnormal ARR [*]	573 / 8,099 (7.1)	162 / 3,542 (4.6)	411 / 4,557 (9.0)	<0.001
Abnormal LRR ^{**}	209 / 8,099 (2.6)	87 / 3,542 (2.5)	122 / 4,557 (2.7)	0.53
AST²				
Abnormal ARR [*]	1,011 / 8,099 (12.5)	434 / 3,542 (12.3)	577 / 4,557 (12.7)	0.58
Abnormal LRR ^{**}	241 / 8,099 (3.0)	123 / 3,542 (3.5)	118 / 4,557 (2.6)	0.02
GGT^{2,3}				
Abnormal ARR [*]	889 / 8,099 (11.0)	362 / 3,542 (10.2)	527 / 4,557 (11.6)	0.06
BR²				
Abnormal ARR [*]	1,051 / 8,099 (13.0)	635 / 3,542 (18.0)	416 / 4,557 (9.1)	<0.001
Abnormal LRR ^{**}	497 / 8,099 (6.1)	214 / 3,542 (6.0)	283 / 4,557 (6.2)	0.75
ALP^{2,4}				
Abnormal ARR [*]	1,161 / 5,616 (20.7)	315 / 2,273 (13.9)	846 / 3,343 (25.3)	<0.001
Abnormal LRR ^{**}	139 / 5,616 (2.5)	60 / 2,273 (2.6)	79 / 2,273 (2.4)	0.513
FIB-4²				
Abnormal ^{***}	99 / 1,877 (5.3)	54 / 824 (6.6)	45 / 1,053 (4.3)	0.03
APRI^{2,5}				
Abnormal ARR ^{****}	145 / 1,877 (7.7)	95 / 824 (11.5)	50 / 1,053 (4.8)	<0.001
Abnormal LRR ^{****}	60 / 1,877 (3.2)	42 / 824 (5.1)	18 / 1,053 (1.7)	<0.001
GPR²				
Abnormal ^{***}	441 / 1,877 (23.5)	185 / 824 (22.5)	256 / 1,053 (24.3)	0.35
AST/ALT²				
Abnormal ^{***}	882 / 8,099 (10.9)	420 / 3,542 (11.9)	462 / 4,557 (10.1)	0.01
S-Index²				
Abnormal ^{***}	73 / 1,877 (3.9)	50 / 824 (6.1)	23 / 1,053 (2.2)	<0.001

¹ p-value calculated to determine whether significant difference between males and females in each category using chi-square test ² ALT - Alanine Transaminase, AST - Aspartate Transaminase, GGT - Gamma-glutamyl transpeptidase, ALP - Alkaline Phosphatase, BR - Total Bilirubin, FIB-4 - fibrosis 4, APRI - AST to Platelet Ratio Index, GPR - GGT to platelet ratio, AST/ALT ratio - Aspartate/ Alanine ratio. ³ LRR for GGT not defined. ⁴ Individuals under the age of 19 were excluded. ⁵ APRI score calculated using ULN of AST using both the ARR and LRR.

* Abnormal LFTs, according to ARR, are defined as test results outside of the following ranges: ALT (Male: 10 – 55 U/L, Female: 7 – 30 U/L), AST (Male: 10 – 40 U/L, Female: 9 – 32 U/L), GGT (Male: 8 – 61 U/L, Female: 5 – 36 U/L), BR (0 – 17 mmol/L), ALP (Male: 45 – 115 U/L, Female: 30 – 100 U/L). ** Abnormal LFTs, according to LRR, are defined as test results outside of the following ranges: ALT (8 – 61 U/L), AST (14 – 60 U/L), BR (2.9 – 37 mmol/L), ALP (48 – 164 U/L). *** Threshold used to predict liver fibrosis: APRI > 0.7. FIB-4 >3.25. GPR >0.32. RPR >0.825. S-Index >0.3

Table 2: Univariate and multivariate analysis for factors associated with abnormal liver function tests according to American reference range (ARR) for ALT, AST, ALP, GGT, and TB, and laboratory markers of fibrosis in adults in the Uganda General Population Cohort.

	ALT ^{1,6} OR (95% CI)	AST ^{1,6} OR (95% CI)	ALP ^{1,4,6} OR (95% CI)	GGT ^{1,6} OR (95% CI)	TB ^{1,6} OR (95% CI)	FIB-4 ^{1,7} OR (95% CI)	APRI ^{1,7,#} OR (95% CI)	GPR ^{1,7} OR (95% CI)	AST/ALT ^{1,7} OR (95% CI)	S-Index ^{3,7} OR (95% CI)
UNIVARIATE ANALYSIS										
Sex										
Male	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Female	2.06 (1.71,2.49)***	1.04 (0.91,1.18) ^{ns}	0.93 (0.84,1.01) ^{ns}	1.15 (1.00,1.32)*	0.46 (0.20,0.24)***	0.64(0.42,0.96)*	0.38 (0.27,0.55)***	1.10 (0.89,1.38) ^{ns}	0.84 (0.73,0.96)*	0.35 (0.21,0.57)***
Age										
<19	Ref	Ref	-	Ref	Ref	Ref ⁵	Ref	Ref	Ref	Ref ⁵
20-29	1.33 (1.03,1.73)*	0.9 (0.73,1.11) ^{ns}	Ref ⁴	2.61 (1.92,3.56)***	1.46 (1.22,1.75)***		2.57 (1.41,4.71)**	2.63 (1.72,4.03)***	0.55 (0.43,0.70)***	
30-39	1.58 (1.22,2.04)***	1.17 (0.95,1.43) ^{ns}	0.72 (0.60,0.87)***	6.59 (5.00,8.72)***	1.15 (0.94,1.39) ^{ns}		3.15 (1.76,5.68)***	6.22 (4.21,9.18)***	0.67 (0.53,0.85)**	
40-49	1.41 (1.04,1.87)*	1.47 (1.12,1.80)***	0.48 (0.38,0.59)***	8.34 (6.29,11.07)***	1.02 (0.83,1.27) ^{ns}	8.48 (3.95,18.18)***	4.00 (2.22,7.18)***	7.63 (5.12,11.36)***	0.83 (0.65,1.05) ^{ns}	5.02 (2.79,9.68)***
50-59	1.38 (1.00,1.90)*	1.57 (1.25,2.00)***	0.82 (0.66,1.02) ^{ns}	8.03 (5.93,10.86)***	0.92 (0.71,1.18) ^{ns}	14.60 (9.86,31.03)***	3.50 (1.80,6.73)***	9.10 (5.91,14.0)***	1.11 (0.86,1.43) ^{ns}	4.71 (2.31,9.59)***
>60	1.39 (1.03,1.88)*	1.24 (0.98,1.55) ^{ns}	1.28 (1.06,1.54)**	6.84 (5.09,9.20)***	0.56 (0.42,0.74)***	34.88 (17.80,68.39)***	3.68 (2.00,7.00)***	8.20 (5.42,12.41)***	2.23 (1.82,2.72)***	5.43 (2.84,10.39)***
Alcohol										
No	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Yes	1.41 (1.16,1.70)***	1.57 (1.35,1.83)***	1.0 (0.86,1.13)***	2.14 (1.83,2.51)***	0.99 (0.85,1.15) ^{ns}	2.02 (1.22,3.32)**	1.60 (1.04,2.31)*	2.10 (1.61,2.66)***	1.28 (1.08,1.50)**	6.09 (3.16,11.72)***
BMI²										
Normal	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Underweight	1.41 (1.12,1.77)**	1.45 (1.23,1.71)***	1.17 (0.96,1.44) ^{ns}	1.42 (1.16,1.73)**	0.69 (0.57,0.83)***	1.78 (1.06,3.00) ^{ns}	1.78 (1.10,2.60)*	1.07 (0.78,1.50) ^{ns}	1.62 (1.37,1.92)***	1.87 (1.04,3.33)*
Overweight	1.10 (0.85,1.41) ^{ns}	0.73 (0.58,0.92)**	0.93 (0.77,1.13) ^{ns}	1.36 (1.11,1.66)**	0.75 (0.59,0.95)*	0.74 (0.35,1.56) ^{ns}	0.91(0.50,1.65) ^{ns}	1.15 (0.82,1.60) ^{ns}	0.57 (0.42,0.76)***	0.87 (0.38,2.03) ^{ns}
HIV status										
Negative	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Positive	1.63 (1.24,2.15)***	2.30 (1.87,2.83)***	1.47 (1.19,1.81)***	4.83 (3.98,5.85)***	0.21 (0.14,0.33)***	0.28 (0.07,1.20) ^{ns}	1.30 (0.68,2.30) ^{ns}	3.88 (2.62,5.73)***	1.06 (0.80,1.42) ^{ns}	4.00 (2.08,7.69)***
HBV status										
Negative	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Positive	2.61 (1.77,3.84)***	2.52 (1.84,3.44)***	1.07 (0.72,1.60) ^{ns}	1.80 (1.24,2.60)***	1.10 (0.76,1.60) ^{ns}	2.01 (0.62,6.50) ^{ns}	3.56 (1.80,7.10)***	4.24 (2.27,7.93)***	0.98 (0.63,0.15) ^{ns}	4.92 (2.07,11.69)***
MULTIVARIATE ANALYSIS										
Sex										
Male	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Female	2.30 (1.89,2.81)***	1.20 (1.04,1.38)*	2.11 (1.83,2.44)***	1.01 (0.86,1.19) ^{ns}	0.46 (0.40,0.53)***	0.62 (0.40,0.97)*	0.42 (0.30,0.62)***	1.11 (0.87,1.41) ^{ns}	0.90 (0.78,1.06) ^{ns}	0.37 (0.22,0.63)***
Age										
<19	Ref	Ref	-	Ref	Ref	Ref ⁵	Ref	Ref	Ref	Ref ⁵
20-29	1.26 (0.95,1.68) ^{ns}	0.89 (0.70,1.12) ^{ns}	Ref ⁴	1.69 (1.19,2.41)**	1.52 (1.25,1.84)***		3.22 (1.66,6.22)**	1.86 (1.19,2.92)**	0.57 (0.44,0.75)***	
30-39	1.35 (1.00,1.80)*	1.00 (0.79,1.27) ^{ns}	0.68 (0.56,0.82)***	3.96 (2.87,5.46)***	1.29 (1.02,1.59)*		3.55 (1.81,7.00)***	3.70 (2.43,5.66)***	0.72 (0.55,0.95)*	
40-49	1.13 (0.83,1.56) ^{ns}	1.20 (0.95,1.52) ^{ns}	0.46 (0.37,0.57)***	4.87 (3.54,6.70)***	1.17 (0.94,1.47) ^{ns}	7.04 (3.19,15.52)***	4.00 (2.04,7.82)***	4.45 (2.88,6.87)***	0.93 (0.71,1.21) ^{ns}	2.68 (1.37,5.26)**
50-59	1.09 (0.77,1.55) ^{ns}	1.29 (0.99,1.67) ^{ns}	0.82 (0.66,1.02) ^{ns}	5.02 (3.58,7.02)***	1.01 (0.78,1.32) ^{ns}	11.29 (5.13,24.80)***	3.45 (1.65,7.22)**	5.75 (3.61,9.15)***	1.22 (0.92,1.61) ^{ns}	2.76 (1.29,5.90)**
>60	1.13 (0.81,1.57) ^{ns}	1.00 (0.78,1.30) ^{ns}	1.32 (1.09,1.59)**	4.98 (3.59,6.90)***	0.60 (0.45,0.80)***	25.15 (12.32,51.35)***	3.50 (1.73,7.11)**	5.39 (3.42,8.47)***	2.20 (1.74,2.77)***	3.34 (1.63,6.84)**
Alcohol										
No	Ref	Ref	-	Ref	-	Ref	Ref	Ref	Ref	Ref
Yes	1.33	1.53 (1.30,1.78)***	-	2.00 (1.69,2.36)***	-	2.05 (1.24,3.40)**	1.51 (1.00,2.27)*	1.96 (1.52,2.54)***	1.26	5.23

		(1.09,1.63)**							(1.06,1.50)**	(2.72,10.04)***
BMI²										
Normal	Ref	Ref	-	Ref	Ref	-	Ref	-	Ref	-
Underweight	1.40 (1.11,1.75)**	1.44 (1.21,1.70)***	-	1.37 (1.11,1.68)**	0.70 (0.58,0.83)***	-	1.72 (1.11,2.65)*	-	1.61 (1.36,1.91)***	-
Overweight	1.12 (0.87,1.44) ^{ns}	0.75 (0.60,0.95)*	-	1.47 (1.19,1.82)***	0.72 (0.57,0.92)**	-	0.95 (0.52,1.73) ^{ns}	-	0.56 (0.42,0.76)***	-
HIV status										
Negative	Ref	Ref	Ref	Ref	Ref	-	-	Ref	-	Ref
Positive	1.59 (1.20,2.10)***	2.13 (1.72,2.63)***	1.47 (1.19,1.81)***	4.76 (3.89,5.82)***	0.22 (0.14,0.34)***	-	-	3.84 (2.58,5.70)***	-	3.58 (1.84,6.94)***
HBV status										
Negative	Ref	Ref	-	Ref	-	-	Ref	Ref	-	Ref
Positive	2.61 (1.76,3.86)***	2.40 (1.74,3.31)***	-	1.65 (1.11,2.45)*	-	-	3.60 (1.79,7.27)***	4.26 (2.23,8.12)***	-	4.37 (1.80,10.58)***

¹ ALT - Alanine Transminase, AST - Aspartate Transminase, GGT - Gamma-glutamyl transpeptidase, ALP - Alkaline Phosphatase, BR -Total Bilirubin, FIB-4 - fibrosis 4, APRI - AST to Platelet Ratio Index, GPR - GGT to platelet ratio, AST/ALT ratio.

² Body Mass Index (BMI) Classification according to WHO (weight/height²: kg/m²): Underweight (<18.5 kg/m²), Normal weight (18.5 – 24.99 kg/m²), Overweight (25.0 – 29.99 kg/m²), Obese (>30.0 kg/m²)

³ An S-index score of >0.3 is suggestive of liver fibrosis

⁴ Individuals under the age of 19 were excluded. Reference age group is 20 – 29

⁵ Reference age group consists of all individuals under the age of 39

⁶ Abnormal LFTs, according to ARR, are defined as test results outside of the following ranges: ALT (Male: 10 – 55 U/L, Female: 7 – 30 U/L), AST (Male: 10 – 40 U/L, Female: 9 – 32 U/L), GGT (Male: 8 – 61 U/L, Female: 5 – 36 U/L), BR (0 – 17 mmol/L), ALP (Male: 45 – 115 U/L, Female: 30 – 100 U/L)

⁷ Threshold used to predict liver fibrosis: APRI > 0.7. FIB-4 >3.25. GPR >0.32. RPR >0.825. S-Index >0.3

[#] APRI score calculated using ULN of AST using African reference range

Significance level: * = (p<0.05), ** = (p<0.01), *** = (p<0.001), ns = (p>0.05)

Table 3: Relative risk, population attributable risk (PAR) percent, and the number of individuals with abnormal liver function tests in the Uganda General Population Cohort. Analysis according to American reference ranges (ARR for ALT, AST, ALP, GGT, and TB)

<i>Variable</i>	<i>ALT</i> ^{1,3}	<i>AST</i> ^{1,3}	<i>ALP</i> ^{1,3}	<i>GGT</i> ^{1,3}	<i>TB</i> ^{1,3}	<i>FIB-4</i> ^{1,4}	<i>APRI</i> ^{1,4,#}	<i>GPR</i> ^{1,4}	<i>AST/ALT</i> ^{1,4}	<i>S-Index</i> ^{2,4}
Alcohol+										
<i>Abnormal Result n (%)</i>	248 (8.5)	467 (16.0)	533 (19.6)	555 (19)	381 (13.1)	72 (11.0)	80 (12.25)	260 (39.8)	379 (13.0)	60 (9.2)
<i>RR (95% CI)</i> ¹	1.4 (1.2 – 1.6)	1.5 (1.4 – 1.7)	1.2 (0.9 – 1.7)	2.9 (2.6 – 3.4)	1.0 (0.9 – 1.1)	5.0 (3.2 – 7.7)	2.3 (1.7 – 3.2)	2.7 (2.3 – 3.2)	1.3 (1.2 – 1.5)	8.7 (4.8 – 15.6)
<i>PAR (%)</i> ^{1,6}	11.3%	15.9%	0.6%	41.3%	0.3%	58.2%	31.3%	37.1%	10.8%	72.7%
<i>Adj. PAR (%)</i> ^{5,6}	10.0%	13.9%	-2.6%	26.7%	1.0%	32.4%	16.2%	19.4%	8.0%	64.0%
HIV+										
<i>Abnormal Result n (%)</i>	71 (11.7)	144 (23.7)	142 (24.8)	227 (37.3)	21 (3.5)	2 (1.6)	14 (11.0)	73 (57.5)	59 (9.7)	15 (11.8)
<i>RR (95% CI)</i> ¹	1.7 (1.4 – 2.2)	2.0 (1.8 – 2.4)	1.2 (1.1 – 1.4)	4.2 (3.7 – 4.8)	0.3 (0.2 – 0.4)	0.3 (0.1 – 1.1)	1.5 (0.9 – 2.5)	2.7 (2.3 – 3.3)	0.9 (0.7 – 1.1)	3.6 (2.1 – 6.1)
<i>PAR (%)</i> ^{1,6}	5.3%	7.3%	2.2%	19.5%	-6.0%	-5.09%	3.1%	10.5%	-0.9%	14.7%
<i>Adj. PAR (%)</i> ^{5,6}	4.3%	6.5%	1.1%	17.6%	-6.0%	-4.6%	1.4%	8.3%	-0.1%	13.6%
HBV+										
<i>Abnormal Result n (%)</i>	33 (15.0)	56 (25.4)	32 (19.5)	39 (17.7)	35 (16)	4 (8.2)	13 (26.53)	25 (51.0)	22 (10.0)	8 (16.3)
<i>RR (95% CI)</i> ¹	2.2 (1.6 – 3.0)	2.1 (1.7 – 2.7)	0.9 (0.7 – 1.3)	1.6 (1.2 – 2.2)	1.2 (0.9 – 1.7)	1.6 (0.6 – 4.1)	1.5 (0.9 – 2.5)	2.2 (1.7 – 3.0)	0.9 (0.6 – 1.4)	4.6 (2.3 – 9.0)
<i>PAR (%)</i> ^{1,6}	3.1%	2.9%	-0.2%	1.7%	0.6%	1.5%	3.1%	3.1%	-0.2%	8.6%
<i>Adj. PAR (%)</i> ^{5,6}	3.3%	2.8%	0.02%	1.4%	0.2%	1.4%	5.7%	2.9%	-0.3%	7.6%

¹ ALT - Alanine Transaminase, AST - Aspartate Transaminase, GGT - Gamma-glutamyl transpeptidase, ALP - Alkaline Phosphatase, BR - Total Bilirubin, FIB-4 - fibrosis 4, APRI - AST to Platelet Ratio Index, GPR - GGT to platelet ratio, AST/ALT ratio - Aspartate/ Alanine ratio, RR - relative risk, PAR (%) - population attributable risk percent, 95% CI denotes 95% confidence interval

² An S-index score of >0.3 is suggestive of liver fibrosis

³ Abnormal LFTs, according to ARR, are defined as test results outside of the following ranges: ALT (Male: 10 – 55 U/L, Female: 7 – 30 U/L), AST (Male: 10 – 40 U/L, Female: 9 – 32 U/L), GGT (Male: 8 – 61 U/L, Female: 5 – 36 U/L), BR (0 – 17 mmol/L), ALP (Male: 45 – 115 U/L, Female: 30 – 100 U/L)








⁴ Threshold used to predict liver fibrosis: APRI > 0.7. FIB-4 >3.25. GPR >0.32. RPR >0.825. S-Index >0.3

⁵ Adjusted for age, sex, alcohol consumption, HBV diagnosis, HIV status, and Body Mass Index.

⁶ A measure of zero indicates of no association between the risk factor and abnormal liver function tests. A positive value indicates that the exposure to the risk factor is a risk factor, while a negative value indicates that it is a protective factor.

APRI score calculated using ULN of AST using African reference range

+ number of abnormal result, RR and PAR (%) are based on individuals who were classified as positives within each variable (ie. Alcohol drinkers, HIV positive, HBV positive)

A**ALT** (n=8075)**B****AST** (n=8074)**C****GGT** (n=8046)**D**Fibrosis score by GPR
(n=1877)Population with GPR>0.32
(n=441)**E**AST/ALT ratio
(n=8099)Population with AST/ALT ≥ 2
(n=888)

Host risk factor

